Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Arbutus Biopharma and BioMarin Pharmaceutical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arbutus Biopharma | 0 | 1 | 0 | 0 | 2.00 |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 3 | 2.80 |
BioMarin Pharmaceutical has a consensus target price of $87.22, suggesting a potential upside of 50.40%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Arbutus Biopharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Arbutus Biopharma | 121.17% | 129.12% | 89.26% |
| BioMarin Pharmaceutical | -0.52% | 5.58% | 3.51% |
Insider & Institutional Ownership
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Arbutus Biopharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
Earnings and Valuation
This table compares Arbutus Biopharma and BioMarin Pharmaceutical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arbutus Biopharma | $14.08 million | 43.98 | -$33.50 million | $1.13 | 3.58 |
| BioMarin Pharmaceutical | $3.22 billion | 3.49 | $348.90 million | ($0.10) | -579.90 |
BioMarin Pharmaceutical has higher revenue and earnings than Arbutus Biopharma. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Arbutus Biopharma on 8 of the 15 factors compared between the two stocks.
About Arbutus Biopharma
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
